| About PER |
|
|
Accreditation
Physicians' Education Resource is accredited
by the Accreditation Council for Continuing Medical Education to
provide continuing medical education for physicians.
Read more.
Disclosure Policy
It is the policy
of Physicians' Education Resource to ensure balance, independence,
objectivity, and scientific rigor
in all of its educational activities. As an organization accredited
by the Accreditation Council for Continuing Medical Education (ACCME),
Physicians' Education Resource requires everyone who is in a position
to control
the content of an educational activity to disclose all relevant financial
relationships with any commercial interest.
Read more. |
|
Call for Case Studies Using Ziconotide for Cancer Pain
Have you treated a patient for cancer pain using ziconotide?
We are now accepting case studies for a CME-designated issue of our publication Case Studies in Pain Management.
For more information, please contact Brian Waggoner at brian.waggoner@pergrouplp.com or at (214) 367-3456. |
|
|
 |
| News Update! |
| Recent
News in Chronic Lymphocytic Leukemia: Highlights
From the 49th Annual Meeting of the American Society of Hematology |
| New Interactive Case Studies |
|
|
|
|
|
|
| New Publications |
|
 |
Optimizing Biologic Therapies in Low-Grade Lymphoma
Improving Outcomes in DLBCL by Altering Current Regimens
Biologic Therapy in CLL: Current Data and Ongoing Studies
Novel Anti-CD20 Antibodies in NHL
Current Trends in Antiangiogenic Therapy in NHL
Therapeutic Approaches to Targeting the Apoptotic Pathway in Lymphoma
1 AMA
PRA Category 1 Credit™
Expiration date: May 15, 2009
|
|
 |
Targeting the VEGFR Axis in RCC
Small-Molecule VEGFR Inhibitors: Integrating Multiple Lines of Therapy for Recurrent RCC
Risk Prognostication and Tumorigenesis in Prostate Cancer
Prevention and Early Intervention in Prostate Cancer
1 AMA
PRA Category 1 Credit™
Expiration date: May 14, 2009 |
|
 |
Lapatinib/Capecitabine for ErbB2-Positive Advanced Breast Cancer
Cardiac Safety of Doxorubicin/Cyclophosphamide Followed by Paclitaxel ± Trastuzumab
Phase II Study of Predictive Biomarker Profiles With Lapatinib in IBC
Trastuzumab/Tanespimycin in Trastuzumab-Refractory ErbB2-Positive Breast Cancer
1 AMA
PRA Category 1 Credit™
Expiration date: May 6, 2009
|
|
 |
ErbB TKIs in ErbB2-Positive IBC
1 AMA
PRA Category 1 Credit™
Expiration date: May 5, 2009
|
|
 |
HDACIs in PTCL
1 AMA
PRA Category 1 Credit™
Expiration date: May 5, 2009
|
| |
|
|
| |
3500 Maple Avenue, Suite 700
Dallas, TX 75219
TEL (888) 949-0045
FAX (214) 367-3305
Copyright © 2008
Physicians' Education Resource
All Rights Reserved
|
| |
